相关实验视频

Updated: Jul 28, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

新辅助免疫治疗加上化疗和辅助向治疗在ALK阳性的非小细胞肺癌中

Qi Song¹, Jie Li², Qi Xiong¹

¹Department of Oncology, 5th Medicial Center, Chinese PLA General Hospital, 28 Fuxing Road, Haidian District, Beijing, 100853, China.

|May 31, 2023

概括

新辅助免疫疗法和化疗后进行手术,再加上辅助克里佐替尼,导致局部晚期非小细胞肺癌 (NSCLC) 患者与ALK融合的完整反应. 这种治疗方法导致36个月的无病生存.

科学领域:

在瘤学瘤学.
胸部外科手术胸部外科手术
医学遗传学医学遗传学

背景情况:

局部发达的非小细胞肺癌 (NSCLC) 与形淋巴瘤激酶 (ALK) 融合突变具有独特的治疗挑战.
在ALK融合NSCLC中新辅助和辅助疗法的疗效尚未得到充分证实.
这一特定的患者亚组的标准治疗方案需要进一步调查.

研究的目的:

报告一种局部发达的NSCLC病例,该病例具有EML4-ALK融合突变,并接受了新辅助免疫疗法和化疗.
评估手术切除和辅助向治疗后的病理反应和长期结果.
突出ALK融合阳性NSCLC的潜在治疗策略.

主要方法:

一名患有EML4-ALK融合突变的IIIB期NSCLC患者接受了新辅助免疫疗法和化疗.
患者接受了叶切除术和淋巴结解剖.
在手术后3个月内使用crizotinib进行辅助治疗.

主要成果:

患者在新辅助治疗和手术后实现了病理完整反应 (pCR).
在治疗后36个月内,维持了无疾病生存期.
新辅助疗法,手术和辅助克里佐替尼的组合显示出显著的疗效.

结论:

新辅助免疫疗法和化疗之后的手术和辅助克里佐替尼可能是局部晚期NSCLC与ALK融合的有效治疗策略.
达到病理完整反应与有利的长期结果有关.
这一案例表明,多式疗法可以克服治疗ALK融合阳性NSCLC的挑战.

关键词:

阿尔克 (ALK) 是一个在NSCLCLC中,我们可以看到.辅助性向治疗是一种辅助性向治疗.检查点抑制剂检查点抑制剂临床免疫学临床免疫学克里佐丁尼布 (crizotinib) 的使用方法新辅助疗法是一种新辅助疗法.这就是Pembrolizumab.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...